Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza Viruses

PLoS Pathogens

Volumn 10, Issue 4, 2014, Pages

  Butler, Jeff ^a,j   Hooper, Kathryn A ^b,c   Petrie, Stephen ^d   Lee, Raphael ^e   Maurer Stroh, Sebastian ^e,f,g   Reh, Lucia ^a   Guarnaccia, Teagan ^a   Baas, Chantal ^a,h   Xue, Lumin ^a   Vitesnik, Sophie ^a   Leang, Sook Kwan ^a   McVernon, Jodie ^d,i   Kelso, Anne ^a   Barr, Ian G ^a,h   McCaw, James M ^d,i   Bloom, Jesse D ^b   Hurt, Aeron C ^a,h  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BIOINFORMATICS INSTITUTE   (Singapore)

^f National Public Health Laboratory   (Singapore)

^g NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^h UNIVERSITY OF BALLARAT   (Australia)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

^j CSIRO   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; OSELTAMIVIR; VIRUS SIALIDASE; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS PROTEIN;

2009 H1N1 INFLUENZA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE TRANSMISSION; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION ASSAY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA; MATHEMATICAL MODEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DOG; FERRET; GENETICS; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; MDCK CELL LINE; MISSENSE MUTATION; REPRODUCTIVE FITNESS;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG RESISTANCE, VIRAL; FERRETS; GENETIC FITNESS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS;

EID: 84901307271     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004065     Document Type: Article

References (60)

1. Hahne S, Donker T, Meijer A, Timen A, van Steenbergen J, et al. (2009) Epidemiology and control of influenza A(H1N1)v in the Netherlands: the first 115 cases. Euro Surveill 14: pii = 19267.
2. Cao B, Li XW, Mao Y, Wang J, Lu HZ, et al. (2009) Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 361: 2507-2517.
3. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, et al. (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50: 2395-2402.
4. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, Grog I, et al. (2008) Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 41: 25-28.
5. NISN (2005) Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 80: 156.
6. Hurt AC, Barr IG, (2008) Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children. Commun Dis Intell Q Rep 32: 57-62.
7. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
8. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, et al. (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55: 307-317.
9. Abed Y, Goyette N, Boivin G, (2004) A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 9: 577-581.
10. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, et al. (2004) Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190: 1627-1630.
11. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O, (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15: 155-162.
12. Moscona A, (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
13. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, et al. (2009) Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 15: 552-560.
14. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, et al. (2009) Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 83: 90-93.
15. Bloom JD, Gong LI, Baltimore D, (2010) Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
16. Bouvier NM, Rahmat S, Pica N, (2012) Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase. J Virol 86: 7268-7279.
17. Abed Y, Pizzorno A, Bouhy X, Boivin G, (2011) Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog 7: e1002431.
18. Wolfe C, Greenwald I, Chen L, (2010) Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. Emerg Infect Dis 16: 1809-1811.
19. Moore C, Galiano M, Lackenby A, Abdelrahman T, Barnes R, et al. (2011) Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 203: 18-24.
20. Chen LF, Dailey NJ, Rao AK, Fleischauer AT, Greenwald I, et al. (2011) Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 203: 838-846.
21. CDC (2009) Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection. Morb Mortal Wkly Rep 58: 969-972.
22. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, et al. (2010) A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 362: 86-87.
23. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, et al. (2012) Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 18: 308-311.
24. Lackenby A, Moran Gilad J, Pebody R, Miah S, Calatayud L, et al. (2011) Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 16: pii = 19784.
25. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, et al. (2011) Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 365: 2541-2542.
26. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, et al. (2012) Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206: 148-157.
27. Hurt AC, Nor'e SS, McCaw JM, Fryer HR, Mosse J, et al. (2010) Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol 84: 9427-9438.
28. NHMRC (2004) Australian code of practice for the care and use of animals for scientific purposes. http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ea16.pdf.
29. Reed LJ, Muench H, (1938) A simple method of estimating fifty per cent endpoints. AM J Epidemiol 27: 493-497.
30. Barr IG, Komadina N, Hurt A, Shaw R, Durrant C, et al. (2003) Reassortants in recent human influenza A and B isolates from South East Asia and Oceania. Virus Res 98: 35-44.
31. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG, (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97: 6108-6113.
32. Bloom JD, Nayak JS, Baltimore D, (2011) A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS One 6: e22201.
33. Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, et al. (2013) Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio 4: e00396-13.
34. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, et al. (2005) Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49: 4075-4084.
35. Hurt AC, Barr IG, Komadina N, Hampson AW, (2004) A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses. Virus Res 103: 79-83.
36. Deng YM, Caldwell N, Hurt A, Shaw T, Kelso A, et al. (2011) A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res 90: 87-91.
37. McCaw JM, Arinaminpathy N, Hurt AC, McVernon J, McLean AR, (2011) A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model. PLoS Comput Biol 7: e1002026.
38. Perelson AS, Ribeiro RM, (2013) Modeling the within-host dynamics of HIV infection. BMC Biol 11: 96.
39. Beauchemin CA, Handel A, (2011) A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Health 11 (Suppl 1): S7.
40. Smith AM, Perelson AS, (2011) Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med 3: 429-445.
41. Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA, (2012) The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. J Virol 86: 10651-10660.
42. Petrie SM, Guarnaccia T, Laurie KL, Hurt AC, McVernon J, et al. (2013) Reducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load. PLoS One 8: e64098.
43. Colman PM, (1994) Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3: 1687-1696.
44. Nayak DP, Hui EK, Barman S, (2004) Assembly and budding of influenza virus. Virus Res 106: 147-165.
45. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, et al. (2008) The influenza virus resource at the National Center for Biotechnology Information. J Virol 82: 596-601.
46. Seibert CW, Kaminski M, Philipp J, Rubbenstroth D, Albrecht RA, et al. (2010) Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 84: 11219-11226.
47. Memoli MJ, Davis AS, Proudfoot K, Chertow DS, Hrabal RJ, et al. (2011) Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis 203: 348-357.
48. Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, et al. (2010) Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog 6: e1001079.
49. Hamelin ME, Baz M, Abed Y, Couture C, Joubert P, et al. (2010) Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 6: e1001015.
50. Abed Y, Pizzorno A, Bouhy X, Rheaume C, Boivin G, (2014) Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus In Vitro, in Mice and in Ferrets. J Virol 88: 1652-1658.
51. Duan S, Boltz DA, Seiler P, Li J, Bragstad K, et al. (2010) Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 6: e1001022.
52. WHO (2013) Influenza. http://www.who.int/influenza/gisrs_laboratory/flunet/en/.
53. Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, et al. (2014) A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill 19: pii = 20666.
54. NIID (2014) Weekly reports of influenza virus isolation/detection, from week 18 of 2013 to week 6 of 2014, Japan. http://www.nih.go.jp/niid/images/iasr/rapid/inf/2014_6w/sinin1e_140206.gif.
55. NIID (2014) Detection of A(H1N1)pdm09 viruses with H275Y mutation in Japan. http://www.nih.go.jp/niid/images/flu/resistance/20140203/dr13-14e20140203-2.gif.
56. CNIC (2014) Chinese Influenza Weekly Report, Week 04 2014. www.cnic.org.cn/eng/show.php?contentid=691.
57. Kelso A, Hurt AC, (2012) The ongoing battle against influenza: Drug-resistant influenza viruses: why fitness matters. Nat Med 18: 1470-1471.
58. Hurt AC, Butler J, Kelso A, Barr IG, (2012) Influenza antivirals and resistance: the next 10 years? Expert Rev Anti Infect Ther 10: 1221-1223.
59. Thorlund K, Awad T, Boivin G, Thabane L, (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11: 134.
60. Hayden FG, (2013) Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 7 (Suppl 1): 63-75.